Cancers, Free Full-Text

Overexpression of Exportin-1 (XPO1), a key regulator of nuclear-to-cytoplasmic transport, is associated with inferior patient outcomes across a range of adult malignancies. Targeting XPO1 with selinexor has demonstrated promising results in clinical trials, leading to FDA approval of its use for multiple relapsed/refractory cancers. However, XPO1 biology and selinexor sensitivity in childhood cancer is only recently being explored. In this review, we will focus on the differential biology of childhood and adult cancers as it relates to XPO1 and key cargo proteins. We will further explore the current state of pre-clinical and clinical development of XPO1 inhibitors in childhood cancers. Finally, we will outline potentially promising future therapeutic strategies for, as well as potential challenges to, integrating XPO1 inhibition to improve outcomes for children with cancer.

Celltracker Zip Get File - Colaboratory

Colon cancer is rising in younger adults. Know the signs and

Know the signs of cancer to catch it early

Event-free Survival with Pembrolizumab in Early Triple-Negative

Cancer Facts and Statistics

Mortality after second malignancy in breast cancer survivors

Cancers, Free Full-Text

Noninvasive detection of any-stage cancer using free

Trastuzumab after Adjuvant Chemotherapy in HER2-Positive Breast

Global estimates of incidence and mortality of cervical cancer in

Prostate Cancer.Csv - Colaboratory

Thoracic Cancer - Wiley Online Library